Qin Lingyan, Chen Xu, Li Ping, Yang Zheng, Mo Wuning
Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, 22 Shuangyong Road, Nanning, 530021, Guangxi, People's Republic of China,
Tumour Biol. 2014 Mar;35(3):2521-8. doi: 10.1007/s13277-013-1333-7. Epub 2013 Nov 6.
The XRCC3 gene has been suggested to play an important role in the pathogenesis of leukemia risk. But the findings of publications are contradictory. To derive a more precise estimation of the association, we performed a meta-analysis. The PubMed, Embase, and China National Knowledge Infrastructure (CNKI) databases were searched for case-control studies published up to August 2013. The pooled odds ratio (OR) and its corresponding 95% confidence interval (CI) were calculated by using a fixed- or random-effect model. A total of 15 case-control studies met the inclusion criteria and were selected. The pooled OR showed that there was no statistically significant association between XRCC3 Thr241Met polymorphism and leukemia risk in overall including studies, while a risky association was observed for acute myeloid leukemia (AML) (dominant model TT/TC vs. CC: OR = 1.240, 95% CI = 1.018-1.511, P = 0.032). The XRCC3 Thr241Met polymorphism might be associated with risk of leukemia in AML. More studies with larger sample sizes are needed to validate this result.
已有研究表明，XRCC3基因在白血病发病风险中起重要作用。但相关研究结果相互矛盾。为更精确地评估两者之间的关联，我们进行了一项荟萃分析。检索了PubMed、Embase和中国知网（CNKI）数据库中截至2013年8月发表的病例对照研究。采用固定效应模型或随机效应模型计算合并比值比（OR）及其相应的95%置信区间（CI）。共有15项病例对照研究符合纳入标准并被选中。合并OR显示，在所有纳入研究中，XRCC3基因Thr241Met多态性与白血病风险之间无统计学显著关联，而在急性髓系白血病（AML）中观察到存在风险关联（显性模型TT/TC与CC相比：OR = 1.240，95%CI = 1.018 - 1.511，P = 0.032）。XRCC3基因Thr241Met多态性可能与AML患者的白血病风险相关。需要更多大样本量的研究来验证这一结果。
